Drugs / EMD640744
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01012102 | Apr 2008 → Oct 2009 | cancer | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMD640744 | “This phase I trial was conducted to test whether vaccine EMD640744, a cocktail of five HLA class I-binding survivin peptides in Montanide(®) ISA 51 VG, promotes anti-survivin...” PMID 24487961 ↗ Feb 2014 |
| Route | Subcutaneous | “administered by subcutaneous injection” NCT01012102 ↗ |